Seeking Alpha
22 Aug 2026, 06:57 UTC · 2h ago
Neurocrine Biosciences: 'House Full Of Options'
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Seeking Alpha
22 Aug 2026, 06:57 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Ingrezza has market exclusivity until 2038 with projected peak sales of $3.3B. — Long-term exclusivity and high peak sales projections provide a predictable, high-value revenue floor for the company.
+0.80Valuation models suggest the stock is undervalued, with targets between $167 and $224 per share. — Significant gaps between current market price and DCF-based valuations typically trigger buying interest from fundamental investors.
+0.60The company is diversifying its growth pillars through the introduction of Crenessity and Vykat XR. — Reducing reliance on a single drug lowers the risk profile and creates additional avenues for revenue growth.
+0.40Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company is rated as a 'Buy' due to strong cash flows, a diversified pipeline, and projected undervaluation.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Seeking Alpha
10h ago
